Skip to main content
. Author manuscript; available in PMC: 2015 Mar 28.
Published in final edited form as: J Control Release. 2014 Jan 23;178:79–85. doi: 10.1016/j.jconrel.2014.01.012

Figure 5. TPM enhanced functionality of PCat-siSurvivin in animal tumors on molecular and cellular levels.

Figure 5

Immunodeficient mice were implanted with tumors and treated as described in the Figure 4 legend. Tumors were excised and processed for immunohistochemical staining and quantitative image analysis of survivin, Ki67, and caspase-3. *p<0.05 between TPM and TPM+PCat-siSurvivin combination.